IDEX Corporation Q1 FY2026 earnings call

IDEX delivered strong first quarter with 5% organic sales growth, 26% adjusted EBITDA margin. Orders grew 10% organically. HST segment showed strong performance. 80-20 strategy used for growth, margin, and execution. Balanced capital deployment including share repurchases and M&A pursuit

HST: Organic orders increased 17%, revenue grew 11% organically, adjusted EBITDA margin expanded 100 basis points year over year. FMT: Organic orders increased 9%, organic sales increased 2%, adjusted EBITDA margin declined 10 basis points year over year. FSDP: Organic orders declined 4%, organic sales decreased slightly, adjusted EBITDA margin increased 30 basis points year over year

Full year 2026 organic growth expected 3 - 4%, adjusted EBITDA margin 26.5% - 27%, adjusted EPS 8.35 - 8.55. Q2 2026 organic growth 3 - 4%, adjusted EBITDA margin 26.5% - 27%, adjusted EPS 2.07 - 2.12

Risks include macroeconomic uncertainty, geopolitical factors impacting business, tariff changes and their potential impact

Q: Just curious on how to think about the guide here...

A: It's around HST continuing growth, FMT flat outlook due to macro uncertainty.

Q: Can you give a bit more context as to why you expect to see maybe some sustained inflection from here in the life sciences portion of HST...

A: Life science business in line with expectations, core franchises growing low single digits, dynamics remain as discussed.